Table 3.

Allogeneic HSCT in 21 CML patients unresponsive to TKIs

Variables	N (%)
Phase of CML at the time of HSCT Chronic phase Accelerated phase Blast phase	11 (52.4) 6 (28.6) 4 (19.0)
Allogeneic HSCT Related donor Unrelated donor Death 0-6 months after HSCT 7-12 months after HSCT Causes of death Graft failure Other complications Patients who survived HSCT 0-1 year after HSCT 1-5 years after HSCT 5-10 years after HSCT	10 (47.6) 11 (52.4) 9 (42.8) 2 (9.5) 3 (14.3) 8 (38.1) 3 (14.3) 4 (19.0) 3 (14.3)